I don't know much about OSIP's pipeline except it's early but maybe Astellas expects positive results from Tarceva's phase III trial in NSCLC patients with mutations in the TK domain of EGFR or approval in maintenance setting. Only possible counterbidder I can think of is Roche but I don't think it will.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.